NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Sells $79,488.00 in Stock

NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo sold 5,175 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares in the company, valued at approximately $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $15.46 on Friday. The stock has a market cap of $1.98 billion, a P/E ratio of -25.34 and a beta of 1.19. NeoGenomics, Inc. has a twelve month low of $12.77 and a twelve month high of $21.22. The stock has a 50 day moving average of $14.63 and a two-hundred day moving average of $14.83. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. NeoGenomics’s revenue for the quarter was up 10.5% on a year-over-year basis. On average, research analysts forecast that NeoGenomics, Inc. will post -0.17 earnings per share for the current year.

Institutional Investors Weigh In On NeoGenomics

Several hedge funds have recently made changes to their positions in the business. Blue Trust Inc. increased its position in NeoGenomics by 107.2% in the 2nd quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 1,206 shares during the period. Quarry LP purchased a new position in shares of NeoGenomics in the 3rd quarter valued at approximately $40,000. Canada Pension Plan Investment Board acquired a new position in shares of NeoGenomics in the second quarter valued at approximately $57,000. KBC Group NV raised its stake in shares of NeoGenomics by 33.1% during the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after purchasing an additional 1,127 shares during the last quarter. Finally, FMR LLC raised its stake in shares of NeoGenomics by 7.6% during the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after purchasing an additional 931 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on NEO shares. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, November 6th. Stephens reiterated an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Benchmark restated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, September 24th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $20.25.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.